Research and registries

Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE) Trial


The PRESERVE (Predicting the Safety and Effectiveness of Inferior Vena Cava Filters) Trial is the first large-scale, multi-specialty, prospective clinical study to evaluate the use of inferior vena cava (IVC) filters and related follow-up treatment in the United States. With the guidance of the Food and Drug Administration (FDA), the study will help determine how well filters prevent pulmonary embolisms and when retrievable filters should be removed, thus advancing patient safety. 

The trial is sponsored by the IVC Filter Study Group Foundation, a joint collaboration between the Society of Interventional Radiology and the Society for Vascular Surgery. 

Currently, the study is recruiting patients. For additional information about participating sites, please visit

<p>To learn more about the trial, please visit the <a title="PRESERVE Trial" href="" target="_blank">PRESERVE</a> website.</p>

To learn more about the trial, please visit the PRESERVE website.


Two PRESERVE Filters Reach Enrollment Cap

As of January 2018, two PRESERVE filters, Option Elite Retrievable and DENALI have reached their 300 subject cap, and enrollment is closed for these filters. A total of 6 filter manufacturers are participating in the trial to reach the overall goal of 1,800 subjects.

  • ALN Implants Chirurgicaux (ALN Vena Cava Filter)
  • Argon Medical Devices, Inc/Rex Medical (Option Elite Retrievable Vena Cava Filter)
  • B. Braun Interventional Systems Inc (VenaTech LP Vena Cava Filter/VenaTech Convertible Filter)
  • Cook Incorporated (Gunther Tulip Vena Cava Filter)
  • CR Bard Peripheral Vascular, Inc (DENALI Vena Cava Filter)
  • Cordis Corporation (OPTEASE Retrievable Vena Cava Filter/TRAPEASE PermanentVena Cava Filter)

The PRESERVE team encourages sites to keep up the excellent work in enrolling patients into other study filters. 


New IVC filter added to PRESERVE Trial

The VenaTech Convertible Filter (B. Braun Interventional Systems Inc.) has been added to the PRESERVE Trial. If your site is using this filter and would like to participate in PRESERVE, please contact Eleanore Moye

What is the significance of the PRESERVE Trial?

Listen to Matthew Johnson, MD, FSIR, the co-chair of the PRESERVE Steering Committee, discuss the background and current status of this important initiative.